The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can pro- mote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL) -25, IL -33 and thymic stromal lymphopoietin (TSLP), known as "alarmins". TSLP, in particular, has been extensively studied as a possible therapeutic target in patients with severe asthma because it is involved in the infla- mmatory processes of both type 2 -high and type 2 -low inflammation. In this regard, tezepelumab (AMG-157/ MEDI-9929), a TSLP-targeted first-in -class fully human monoclonal antibody, has been shown in phase II and III studies to be effective and safe in treating patients with severe asthma, regardless of the underlying endo- type or phenotype and irrespective of baseline bio- markers, such as blood eosinophil count and fraction of exhaled nitric oxide. Here, we provide a comprehen- sive review of TSLP function in airway inflammatory processes, the clinical development of tezepelumab for severe asthma as well as its possible future indications.
Tezepelumab for asthma
Pelaia, Corrado;
2022-01-01
Abstract
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can pro- mote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL) -25, IL -33 and thymic stromal lymphopoietin (TSLP), known as "alarmins". TSLP, in particular, has been extensively studied as a possible therapeutic target in patients with severe asthma because it is involved in the infla- mmatory processes of both type 2 -high and type 2 -low inflammation. In this regard, tezepelumab (AMG-157/ MEDI-9929), a TSLP-targeted first-in -class fully human monoclonal antibody, has been shown in phase II and III studies to be effective and safe in treating patients with severe asthma, regardless of the underlying endo- type or phenotype and irrespective of baseline bio- markers, such as blood eosinophil count and fraction of exhaled nitric oxide. Here, we provide a comprehen- sive review of TSLP function in airway inflammatory processes, the clinical development of tezepelumab for severe asthma as well as its possible future indications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
